GlassScriptPhysician profile
Tamer Yacoub
NPI 1578557807
$775,288.07
in general payments reported to CMS, 2019-2025
62 companies · $173K in 2025
The $173K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $118K · 2020: $45K · 2021: $54K · 2022: $172K · 2023: $114K · 2024: $100K · 2025: $173K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $273K · Travel and Lodging: $37K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $22K · Food and Beverage: $19K · Consulting Fee: $17K · Honoraria: $17K · Education: $178 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $272,862.13 |
| Travel and Lodging | $37,290.66 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $22,268.75 |
| Food and Beverage | $19,164.90 |
| Consulting Fee | $17,295.00 |
| Honoraria | $17,155.00 |
| Education | $178.44 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $248,533.50 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $214,360.23 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Corcept Therapeutics | $52,622.41 | 2019-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $37,333.95 | 2021-2025 | |
| Abbott Laboratories | $32,767.47 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Ascendis Pharma Endocrinology INC | $32,486.90 | 2025 | Yorvipath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27,665.99 | 2019-2025 | Jardiance, Synjardy |
| Amryt Pharma Holdings LTD | $27,264.55 | 2020-2023 | Myalept |
| Esperion Therapeutics, INC. | $16,602.85 | 2020-2025 | Nexletol |
| Xeris Pharmaceuticals, INC. | $15,604.86 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Aegerion Pharmaceuticals, INC. | $14,837.06 | 2019 | |
| Abbvie INC. | $13,110.54 | 2019-2025 | Synthroid |
| Merck Sharp & Dohme LLC | $10,802.83 | 2019-2023 | Verquvo, Steglatro, Steglujan |
| Sanofi-Aventis U.S. LLC | $9,279.74 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $7,431.05 | 2019-2020 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $4,016.98 | 2024 | |
| Eli Lilly and Company | $2,250.00 | 2019-2023 | |
| Amgen INC. | $1,701.05 | 2019-2025 | Evenity, Repatha, Tepezza |
| Astrazeneca Pharmaceuticals LP | $1,495.51 | 2019-2025 | Farxiga |
| Zealand Pharma US, INC. | $750.00 | 2021 | |
| Amarin Pharma, INC. | $641.78 | 2019-2022 | |
| Mannkind Corporation | $605.67 | 2020-2025 | Afrezza |
| Cequr Corporation | $358.54 | 2023-2025 | Cequr Simplicity |
| Kyowa Kirin, INC. | $336.00 | 2023-2025 | Crysvita |
| Alexion Pharmaceuticals, INC. | $193.45 | 2021-2025 | Strensiq |
| Tandem Diabetes Care, INC. | $191.31 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $188.15 | 2019-2025 | Dexcom G6 Transmitter |
| Sequel Med Tech, LLC | $163.95 | 2025 | Twiist |
| Novartis Pharmaceuticals Corporation | $160.80 | 2019-2025 | |
| Lexicon Pharmaceuticals, INC. | $110.01 | 2023-2024 | Inpefa |
| Glaxosmithkline, LLC. | $109.73 | 2022-2025 | Shingrix |
| Amneal Pharmaceuticals LLC | $105.20 | 2023-2025 | Unithroid |
| Inari Medical, INC. | $101.09 | 2022 | |
| Medtronic, INC. | $98.13 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Antares Pharma, INC. | $85.66 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $75.05 | 2019 | |
| Insulet Corporation | $73.66 | 2019-2025 | Omnipod |
| Madrigal Pharmaceuticals | $72.88 | 2025 | Rezdiffra |
| Lifescan, INC. | $55.64 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $53.79 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $50.06 | 2019-2022 | |
| Pfizer INC. | $46.32 | 2024 | |
| Currax Pharmaceuticals LLC | $45.12 | 2024-2025 | Contrave |
| Kowa Pharmaceuticals America, INC. | $44.10 | 2019-2022 | |
| Chiesi USA, INC. | $43.56 | 2024-2025 | Myalept, Mycapssa |
| Radius Health, INC. | $39.88 | 2024 | Tymlos |
| Shire North American Group INC | $36.81 | 2019 | |
| Recordati_rare_diseases_inc. | $33.42 | 2025 | Isturisa |
| Nevro Corp. | $31.54 | 2021 | |
| Ibsa Pharma INC. | $31.53 | 2019-2020 | |
| Horizon Therapeutics Plc | $31.03 | 2023 | Tepezza |
| Alnylam Pharmaceuticals INC. | $26.75 | 2020 | |
| Rgh Enterprises LLC | $24.97 | 2025 | |
| Tolmar, INC. | $24.29 | 2025 | Jatenzo |
| Valeritas, INC. | $21.12 | 2019 | |
| Lucid Diagnostics INC. | $17.39 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $16.60 | 2021 | |
| Vifor Pharma, INC. | $12.88 | 2019 | |
| Janssen Scientific Affairs, LLC | $12.74 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$40,199.45 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamer Yacoub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.